Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance

Ascendis Pharma A/STrade
iShares iBoxx $ Inv Grade Corporate Bond ETFTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Ascendis Pharma A/S trades at $255.33 (market cap $16.67B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.24. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

ASNDLQD
Market Cap
$16.67B
Sector
Health
52-Week High
$277.18$112.91
52-Week Low
$189.74$105.96
Enterprise Value
$17.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.

ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.

iShares iBoxx $ Inv Grade Corporate Bond ETF

LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, trades at $106.335, up 0.35% today, while technical indicators signal a bearish trend with moving averages and key oscillators in sell or neutral territory. The ETF has declared several dividends for 2026, with payments scheduled through August, reflecting its income-focused strategy amid fluctuating bond markets driven by inflation fears and geopolitical tensions.

The outlook for LQD is cautious due to bearish technicals and macroeconomic pressures like rising oil prices and potential Fed rate hikes, which could pressure corporate bond yields. Investors may find value in its investment-grade corporate debt exposure for diversification, but must monitor interest rate volatility and economic data closely for risks to fixed income returns.

Returns comparison

Trailing returns across standard periods

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About iShares iBoxx $ Inv Grade Corporate Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.

Read more on LQD